Maze Therapeutics, Inc. (MAZE) Form 8-K — Oct 16, 2026

Maze Therapeutics entered into an exchange agreement dated October 15, 2026 with Frazier Life Sciences funds to exchange 2,776,007 shares of common stock for pre-funded warrants to purchase an identical number of shares at a $0.001 exercise price. The exchange was completed under the Section 3(a)(9) registration exemption, meaning no new securities were sold and no cash was raised. The warrants carry a 9.99% beneficial ownership cap and holders have no voting rights on the underlying shares beyond Delaware law requirements. After the exchange, Maze reported 53,931,889 shares of common stock outstanding as of October 16, 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.